Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 in Perioperative Treatment of Resectable Hepatocellular Carcinoma
NCT06930573Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ivonescimab in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Started Dec 2024; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06930573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06930573.